Biocon on Q3 earnings performance

CNBC-TV18 2019-01-25

Views 152

Biosimilars business is a very capital intensive and investment intensive in terms of R&D and we will need to raise capital either through private equity or IPO, said Kiran Mazumdar Shaw, Chairperson & MD, Biocon.

Share This Video


Download

  
Report form